Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP625425.RAVi_QzjP3QnhtkwiJMxneXFGuj3jASMQJxPR-aEY--K0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP625425.RAVi_QzjP3QnhtkwiJMxneXFGuj3jASMQJxPR-aEY--K0130_assertion type Assertion NP625425.RAVi_QzjP3QnhtkwiJMxneXFGuj3jASMQJxPR-aEY--K0130_head.
- NP625425.RAVi_QzjP3QnhtkwiJMxneXFGuj3jASMQJxPR-aEY--K0130_assertion description "[The role of PI3K and MAPK pathways in tumor initiation and progression is well established; hence, several inhibitors of these pathways are currently in different stages of clinical trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP625425.RAVi_QzjP3QnhtkwiJMxneXFGuj3jASMQJxPR-aEY--K0130_provenance.
- NP625425.RAVi_QzjP3QnhtkwiJMxneXFGuj3jASMQJxPR-aEY--K0130_assertion evidence source_evidence_literature NP625425.RAVi_QzjP3QnhtkwiJMxneXFGuj3jASMQJxPR-aEY--K0130_provenance.
- NP625425.RAVi_QzjP3QnhtkwiJMxneXFGuj3jASMQJxPR-aEY--K0130_assertion SIO_000772 22684718 NP625425.RAVi_QzjP3QnhtkwiJMxneXFGuj3jASMQJxPR-aEY--K0130_provenance.
- NP625425.RAVi_QzjP3QnhtkwiJMxneXFGuj3jASMQJxPR-aEY--K0130_assertion wasDerivedFrom befree-20150227 NP625425.RAVi_QzjP3QnhtkwiJMxneXFGuj3jASMQJxPR-aEY--K0130_provenance.
- NP625425.RAVi_QzjP3QnhtkwiJMxneXFGuj3jASMQJxPR-aEY--K0130_assertion wasGeneratedBy ECO_0000203 NP625425.RAVi_QzjP3QnhtkwiJMxneXFGuj3jASMQJxPR-aEY--K0130_provenance.